mTOR pathway inhibitors differently effect proliferation and gene expression in pancreatic and pulmonary NET cell lines

#3188

Introduction: The mammalian target of rapamycin (mTOR) is part of the PI3K/Akt/mTOR signalling pathway which has a central role in the oncogenesis of neuroendocrine tumors (NETs). Everolimus (EVE), an mTOR inhibitor, has shown effective in delaying progression of advanced NETs, but with a limited long-term efficacy, possibly due to a compensatory activation of the PI3K/AKT signalling. BYL719, a PI3K inhibitor, was shown to inhibit growth of several NET cell line models.

Aim(s): To compare the effect of mTOR, PI3K or dual mTOR/PI3K inhibition on cell proliferation and transcriptome profile of pancreatic (BON-1) and pulmonary (H727) NET cell lines.

Materials and methods: Proliferation was assessed by MTT cell viability and colony formation assays. Differential gene expression and pathway analyses were performed based on RNA sequencing.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Mor-Cohen R

Authors: Mor-Cohen R, Braiman N, Tirosh A,

Keywords: NET cell lines, PI3K/Akt/mTOR signalling, Wnt signalling, everolimus, BYL719,